Multiple Sclerosis (MS) is a chronic autoimmune disorder that affects the central nervous system (CNS), specifically the brain and spinal cord. It is characterized by demyelination, which is the destruction of the protective myelin sheath surrounding nerve fibers, gliosis, which involves scarring or hardening of neural tissue, and neuronal loss, leading to impaired communication between the brain and the rest of the body. The resulting symptoms vary widely among patients, including fatigue, muscle weakness, loss of coordination, visual disturbances, and cognitive impairment.

The Regentime Procedure offers an innovative, regenerative approach to treating Multiple Sclerosis. Unlike conventional treatments that focus primarily on slowing disease progression or managing symptoms, Regentime aims to restore and repair damaged neural tissue. This is achieved through the use of autologous stem cells, harvested from the patient’s own body, which are processed and reintroduced to target damaged areas within the CNS.

Stem cells possess remarkable biological properties that make them suitable for MS treatment. They can modulate the harmful effects of reactive oxygen and nitrogen species—both of which contribute to neural inflammation and degeneration. In addition, they stimulate the secretion of anti-inflammatory cytokines, reducing the autoimmune response that attacks myelin. Furthermore, stem cells can differentiate into neuronal and glial cells, enabling them to regenerate damaged tissue and potentially restore neurological function.

The Regentime protocol has been applied to patients with all major types of Multiple Sclerosis, including:

•Relapsing Remitting Multiple Sclerosis (RRMS)

•Primary Progressive Multiple Sclerosis (PPMS)

•Secondary Progressive Multiple Sclerosis (SPMS)

•Progressive Relapsing Multiple Sclerosis (PRMS)

Each patient undergoes a personalized treatment plan, determined by their specific medical history, disease stage, and overall health status.

The full Regentime procedure for MS typically requires a five-day stay in Lebanon, during which the patient undergoes evaluation, cell harvesting, preparation, and reinfusion. The cost of treatment varies depending on case complexity and procedural customization, generally ranging from 25,000 USD to 34,000 USD.

By combining regenerative medicine with a precise, patient-centered methodology, the Regentime procedure represents a promising therapeutic option for individuals seeking to improve neurological function and quality of life beyond what conventional therapies can achieve.